comparemela.com

Latest Breaking News On - Lupkynis - Page 1 : comparemela.com

In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning

Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management

United statesAurinia lupkynisAstrazeneca saphneloMaxine yarnall spherixEuropean unionSpherix networkGlobal insightsPatient chart dynamixRealworld dynamixChart dynamixSpherix global insightsSpherix global insightYarnall spherix global insightsSystemic lupus erythematosusLupus nephritisKidney disease

Aurinia Pharmaceuticals Inc : Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option

United statesUnited kingdomGreat britainPeter greenleafAurinia pharmaceuticalsNational institute for healthAurinia pharmaceuticals incHealthcare products regulatory agencyNational instituteCare excellenceChief executive officerEuropean commission approvedRed cell aplasiaDrug interactionsModerate hepatic impairmentPrescribing information

Otsuka s Lupkynis receives NICE green light

Recommendation applies across England and Wales and the treatment is available now - News - PharmaTimes

United kingdomGreat britainPaul howardRyan gynneOtsuka pharmaceuticalsHealthcare products regulatory agencyNational institute for healthNational instituteCare excellence

AURINIA PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure. On April 5, 2023, Aurinia Pharmaceuticals Inc. announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the. | April 5, 2023

Securities exchangeAurinia pharmaceuticals incCurrent reportSecurities exchange actSecurities actAnnouncing positive topline dataInvestor presentationPage interactive data fileEdgar onlineAurinia pharmaceuticals inc stock exchangePress releaseOr auph ca05156v1022

Otsuka receives vital Lupkynis MHRA authorisation

Therapy represents first oral calcineurin-inhibitor treatment for active lupus nephritis in adults - News - PharmaTimes

United kingdomRyan gynneHealthcare products regulatory agency

vimarsana © 2020. All Rights Reserved.